In this review, we discuss how the unique dependence of HSC on the MPL–THPO axis together with the unusual pathophysiology of MPL in the MPN, creates a therapeutic target of opportunity to suppress MPN HSC while sparing normal HSC. The gene discussed is MPL; the disease is myeloproliferative neoplasm.